# OnCo record nct04701476 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04701476/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04701476", "NCT04701476" ;
  schema:name "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC"@en ;
  schema:description "A phase 2 trial of Pembrolizumab, Trifluridine/tipiracil, Regorafenib in colorectal cancer, run by Teclison Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04701476/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04701476> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2021-05-20" ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/trifluridine-tipiracil/>, <https://onco.cc/drugs/regorafenib/> ;
  onco:companies <https://onco.cc/companies/teclison/> .